Retrophin (RTRX)'s Board Of Directors Appoints John W. Kozarich, Ph.D. As Independent Director And Names Jeffrey A. Meckler As Chairman

SAN DIEGO--(BUSINESS WIRE)--Retrophin, Inc. (NASDAQ:RTRX) today announced the appointment of Dr. John W. Kozarich to the Board of Directors as an independent director, effective immediately. Retrophin also announced its Board of Directors has named Jeffrey A. Meckler as the Company's next Chairman of the Board of Directors, effective after the annual meeting of stockholders to be held later this year. Mr. Meckler, a director since 2014, will succeed current Chairman Steve Richardson, who has chosen not to stand for re-election.

Suggested Articles

EQRx is adding a pair of PD-1/PD-L1 meds to its pipeline through a deal with CStone worth $150 million upfront but could net the latter $1.15 billion.

All eyes are on Pfizer’s COVID-19 vaccine work, but the Big Pharma has today quietly culled two midstage trials and one phase 1 test.

All subjects had lower extremity weakness after receiving antisense oligonucleotide GTX-102, leading Ultragenyx to pause the study.